8-K: ReShape Lifesciences Faces Nasdaq Delisting Threat Over Equity Shortfall, Plans Appeal

ReShape Lifesciences Inc. has received a notice from Nasdaq indicating its securities will be delisted due to non-compliance with the minimum stockholders' equity requirement, prompting the company to initiate an appeal.

Summary

• On May 28, 2025, ReShape Lifesciences Inc. received a written notice from The Nasdaq Stock Market's Listing Qualifications Department stating Nasdaq's determination to delist the company's securities.
• This delisting determination stems from the company's failure to comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, as set forth in Nasdaq Listing Rule 5550(b).
• Nasdaq had previously notified the company of this non-compliance on November 25, 2024, and granted an extension until May 27, 2025, which the company failed to meet.
• Unless the company requests an appeal by June 4, 2025, trading of its common stock will be suspended at the opening of business on June 6, 2025, followed by the filing of a Form 25-NSE to remove its securities from listing and registration.
• ReShape Lifesciences Inc. intends to appeal Nasdaq's decision to a hearings panel, which would temporarily stay the suspension of its securities pending the panel's decision.
• The company provides no assurance that the hearings panel will grant its request for continued listing or that it can maintain compliance with other Nasdaq Listing Rules.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the formal delisting notice from Nasdaq, indicating severe non-compliance with listing requirements and significant uncertainty regarding the company's future public trading status. While an appeal is planned, there is no assurance of success.

Negatives

• The company received a formal notice of delisting from Nasdaq.
• ReShape Lifesciences Inc. failed to meet the minimum $2,500,000 stockholders' equity requirement for continued listing.
• The company did not meet the terms of the extension granted by Nasdaq, which expired on May 27, 2025.
• Trading of the company's common stock is scheduled for suspension on June 6, 2025, if an appeal is not filed or is unsuccessful.
• There is no assurance that the appeal will be successful or that the company can maintain compliance with other Nasdaq Listing Rules.

Risks

• Risk of delisting from The Nasdaq Capital Market, which would significantly impact the liquidity and marketability of the company's common stock.
• Failure to regain compliance with Nasdaq's minimum stockholders' equity requirement.
• Uncertainty regarding the outcome of the appeal to Nasdaq's hearings panel.
• Potential inability to maintain compliance with other Nasdaq Listing Rules even if the current appeal is successful.

Future Outlook

ReShape Lifesciences Inc. intends to appeal Nasdaq's delisting decision, which would temporarily stay the suspension of its securities. However, the company provides no assurance that the appeal will be successful or that it can maintain compliance with other Nasdaq Listing Rules, indicating an uncertain future regarding its public listing status.

Management Comments

• Paul F. Hickey, Chief Executive Officer, signed the report indicating the company's formal acknowledgment of the delisting notice and its intent to appeal.

Industry Context

The potential delisting of ReShape Lifesciences Inc. from Nasdaq highlights the stringent compliance requirements for publicly traded companies. Failure to meet financial thresholds, such as minimum stockholders' equity, can lead to loss of listing, significantly impacting a company's access to capital markets, investor confidence, and liquidity. This situation underscores the ongoing challenges smaller life sciences companies may face in maintaining public listing status amidst financial pressures.

Comparison to Industry Standards

• This document does not provide specific financial or operational data points for direct comparison to industry-specific benchmarks or comparable companies' performance. The focus is solely on a regulatory compliance issue related to listing standards.

Stakeholder Impact

• Shareholders: Face significant risk of reduced liquidity and marketability of their common stock due to potential delisting from Nasdaq, which could lead to a substantial decrease in share price.
• Investors: Potential loss of confidence in the company's financial stability and governance, making it less attractive for future investments.
• Employees: While not directly mentioned, delisting can sometimes lead to operational restructuring or reduced access to capital, potentially impacting employees.

Next Steps

• ReShape Lifesciences Inc. must request an appeal of Nasdaq's delisting determination by June 4, 2025.
• The company will proceed with a hearing before a Nasdaq hearings panel to present its case for continued listing.
• If the appeal is unsuccessful or not filed, trading of the company's common stock will be suspended on June 6, 2025.
• A Form 25-NSE will be filed with the SEC to formally remove the company's securities from listing and registration on Nasdaq if delisting proceeds.

Key Dates

Recommendation

Keywords

ReShape Lifesciences, RSLS, Nasdaq, Delisting, Stockholders' Equity, Listing Rules, Appeal, SEC Filing, 8-K, Corporate Governance